A Clinical Study Of Renshenjiechengdecoction Treatment On Alcoholic Fatty Liver Disease:Noninvasive Assessment Of Steatosis With Controlled Attenuation Parameter Using Fibroscan~?

Objective:(1)To observe the usefulness and safety of Renshenjiecheng decoction on alcohol fatty liver disease (AFLD).(2)To observe controlled attenuation parameter for noninvasiveassessment of steatosis using Fibroscan:validation in AFLD and finally to provide a new, effective way of diagnosing AFLD.MethodsTo use prospective study RCT for clinical scheme design.88 patients were randomly, single blind devided into experimental group (44 cases) and control group (cases).The patients took Renshenjiecheng decoctionin the treatment.For the control group used in treatment of Polyene Phosphatidylcholine Capsules. The course of treatment was 12 weeks. To observe the liver image learns in ultrasound (US), the normalisation of controlled attenuation parameters, biochemical responses, blood level of MCV, TCM syndrome score, SF-36 scale scores, and adverse reaction.Results1.Forty-two and forty-one participants concluded the study in the treatment group and control group respectively.In the experimental group 2 subjects did not complete the study.1 withdrew from the study,1 did not come for the final Fibroscan~? follow-up. Similarly, in the control group 3 subjects did not complete the study,1 withdrew from the study,1 were excluded for protocol violation,1 missed final Fibroscan~?.2.The difference in the age, sex, BMI, baseline of AST,ALT,GGT,TC,TG and MCV levels, hepatic steatosis grade in US, CAP value, TCM syndrome score and SF-36 scale scores was not statistically significant (p>0.05) between experimental group and control group.3.TCM syndrome score:compared with pre-treatment,TCM syndrome score of the two groups were both decreased (p<0.01), and the experimental group was more effective (p<0.01).4.SF-36 scale scores:compared to control group, after the 12 weeks'treatment,the factors were improve more significantly (p<0.05).5.Biochemical and MCV responses:after the 12 weeks"treatment,the levels of ALT,AST and GGT in two groups were significantly decreased(p<0.05), and the recovery rate of ALT,AST and GGT in the experimental group was significantly higher than that in the control group(p<0.05). In depressing TC and TG, the experimental group was better than the control group(p<0.05).The levels of MCV in the two groups were decreased(p<0.01),but the recovery rate was no significant difference between the two groups(p>0.05).6.CAP score:compared with pre-treatment, CAP score of the two groups were both decreased (p<0.01), and the experiment group was more effective (p<0.01).7.ultrasound:The total effective rate was 87.5%,64.1% respectively in the experimental group and control group (p<0.05). v8.Adverse reactions:the two group of patients with no serious adverse reactions reported or the conditions turn for the worse.ConclusionThe clinical observation of the groups who take Renshenjiecheng decoction and Polyene Phosphatidylcholine Capsules proves that Renshenjiecheng decoction can improve clinical syndromes reduce, TCM syndrome,the quality of life and reduce steatosis.Therefore, Renshenjiechengdecoction can be safe,effective in treatment of alcoholic fatty liver.Meanwhile, The CAP score is well correlated with hepatic steatosis. CAP implemented on Fibroscan~? is noninvasive,repeatable and has a good application prospect in the diagnosis and curative effect evaluation of AFLD.